Amendment 2 to the License Agreement entered into by AnalytiCon Discovery GmbH and Pharvaris NV on 31 st March 2016, This Amendment 2 is made between Pharvaris Netherlands BV Emmy Noetherweg 2, 2333 BK Leiden, The Nether

AnalytiCon Discovery GmbH and Pharvaris NV on 31st March 2016,

This Amendment 2 is made between

Pharvaris Netherlands BV

Emmy Noetherweg 2, 2333 BK Leiden, The Netherlands

Darmst dter Str. 34 - 36, 64673 Darmstadt, Germany

BRAIN Biotech and Pharvaris in the following also referred to individually as Party

or collectively as Parties

This Amendment 2 to License Agreement ( Amendment 2 ) is dated as of September 20, 2024 by and between Pharvaris Netherlands BV, a company with limited liability incorporated in the Netherlands ( Pharvaris ), and BRAIN Biotech AG, a stock corporation incorporated in Germany ( BRAIN Biotech ). Capitalized terms used and not defined in this Amendment 2 have the meanings assigned to them in the License Agreement.

WHEREAS, Pharvaris NV (FKA Pharvaris BV) and AnalytiCon Discovery GmbH ( AnalytiCon ) have entered into that certain License Agreement, dated as of March 31, 2016, as assumed by Pharvaris which replaced Pharvaris NV by way of an Assumption of Contract dated as of January 21/23, 2020 and as amended by that certain Amendment 1, dated as of January 9, 2021 ( Amendment 1 ; the License Agreement, as amended from time to time, the License Agreement );

WHEREAS, AnalytiCon has transferred the License Agreement to BRAIN Biotech by way of a merger between AnalytiCon and BRAIN Biotech, effective as of June 6, 2024;

WHEREAS, BRAIN Biotech has proposed to sell, transfer and assign its right, title and interest in the payments BRAIN Biotech receives from Pharvaris pursuant to Section 5.3 of the License Agreement (subject to, as the case may be, reductions pursuant to Sections 5.5, 5.6, 6.4.4, 10.3.3, and 12.2.4 of, or otherwise pursuant to and in accordance with, the License Agreement) to Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle ( Royalty Pharma ) on terms and conditions customary for such a monetization transaction, including the grant for the benefit of Royalty Pharma of a security interest in the License Agreement (the RP Monetization ); and

WHEREAS, at the occasion of, but independently from, the RP Monetization, the Parties desire to amend the License Agreement to clarify certain terms related to the duration of the Pharvaris payment obligations under the License Agreement, as set forth herein.

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby amend the License Agreement and agree as follows:

I.After Section 1.27, the following new Section 1.27A is hereby added:

1.27A Royalty-Bearing Product(s) shall mean any Licensed Product containing a compound within the scope of the Markush general formula (I) of claim 1 of US Patent No. 10,836,748. Each of deucrictibant (PHVS121), PHVS416 and PHVS719 is a Royalty-Bearing Product.

II.In Sections 1.13, 1.17, 1.22, 5.2, 5.3, 5.6, and 6.1 the words Licensed Product(s) (or corollary phrases Licensed Product or Licensed Products as applicable) are replaced by the words Royalty-Bearing Product(s) (or corollary phrases Royalty-Bearing Product or Royalty-Bearing Products as applicable).

III.Section 1.28 is reworded as follows:

1.28 Sublicensee shall mean such a Third Party which receives a commercial sublicense from Pharvaris under the Exclusive License to develop, market and sell Licensed Products(s) on its own account (and, if applicable, which is obligated to make payments to Pharvaris on the basis of royalty payments on Net Sales of Royalty-Bearing Product(s)).

IV.Section 4.2 is reworded as follows:

The Exclusive License includes the right of Pharvaris to grant sublicenses within the scope of the Exclusive License to its Affiliates or Third Parties to develop, market and sell Licensed Product(s) on its own account (if applicable, on the basis of royalty payments by Pharvaris to AnalytiCon on Net Sales of Royalty-Bearing Product(s) by such Sublicensees as further defined in this Agreement).

V.In Section 5.4, the words Product are replaced by words Royalty-Bearing Product containing deucrictibant , and the words Backup Product are replaced by the words Royalty-Bearing Product not containing deucrictibant .

VI.In Section 5.5, the words Product are replaced by the words Royalty-Bearing Product .

VII.Section 5.7.2 is reworded as follows:

The Term of royalty payments with respect to each Royalty-Bearing Product shall be the Term with respect to such Royalty-Bearing Product.

VIII.In the first sentence of Section 10.1, the words the expiry of the last Patent of the Licensed IP (the Term ). are replaced by the following words:

(a) with respect to each Royalty-Bearing Product, the Expiration of the last Valid Claim of a Royalty-Bearing Patent that claims such Royalty-Bearing Product, on a Royalty-Bearing Product-by-Royalty-Bearing Product basis, and (b) with respect to each Licensed Product that is not a Royalty-Bearing Product, the Expiration of the last Valid Claim of a Non-Royalty-Bearing Patent that claims such Licensed Product, on a Licensed Product-by-Licensed Product basis (the Term ).

IX.At the end of Section 10.1, the following new paragraphs are added:

Valid Claim means a claim of a Patent, including as such claim may be extended, whether through a patent term extension, supplementary protection certificate or otherwise, that has not expired, lapsed, been cancelled, abandoned or waived, or been dedicated to the public, disclaimed, rejected or held unenforceable, invalid, revoked or cancelled by a court or administrative agency of competent jurisdiction in an order or decision from which no appeal has been or can be taken, including through opposition, re-examination, reissue, disclaimer, inter partes review, inter partes review post grant procedures or similar

proceedings, and that has not otherwise become, or turned out to be, ineffective in whatever form and on whatever legal grounds. Expiration means any of the cases of ineffectiveness addressed in the preceding sentence.

Royalty-Bearing Patent means (a) US Patent No. 10,836,748 and (b) any patent or patent application (including any international patent or patent application) that shares a common priority with US Patent No. 10,836,748. The Patents listed on Schedule A are the Royalty-Bearing Patents that exist as of the date of this Amendment 2.

Non-Royalty-Bearing Patent means any Patent owned or controlled by Pharvaris that claims a Licensed Product that is not a Royalty-Bearing Product.

X.The schedule attached hereto as Schedule A is hereby appended to, and incorporated into, the License Agreement as a new Schedule A.

XI.The License Agreement shall stay in force to the extent not explicitly amended by this Amendment 2.

XII.This Amendment 2 shall only come into effect (and, subject to the terms and conditions of the License Agreement, remain in effect) upon the condition that the Consent Letter, as specified in Exhibit D-2 to the Royalty Purchase Agreement between Brain Biotech and Royalty Pharma, is duly executed and becomes effective among Brain Biotech, Pharvaris, and Royalty Pharma.

Remainder of page blank; signature page follows.

IN WITNESS THEREOF, the Parties hereto have caused this Amendment 2 to be executed in duplicate by their respective duly authorized representatives.

Signature Page to Amendment 2